Publications

467 publications

Enter search criteria
Fill in keyword(s) to narrow your search.
Period
You can select a specific type of a publication you are looking for, such as press releases or speeches
Sort by:
  1. Moving towards new health care and new health care professions (the contours)

    This report is a summary of recommendations by Zorginstituut Nederland. The original text is in Dutch.

    Report | 10-04-2015

  2. Assessment of established medical science and medical practice

    In this report we describe, ‘anno today’, how we assess the criterion ‘established medical science and medical practice‘ and ...

    Report | 19-01-2015

  3. Taking care of good healthcare

    Video | 12-12-2014

  4. Febuxostat (Adenuric) for the treatment of chronic hyperuricaemia

    In conclusion, febuxostat can be said to have an equal value in comparison to allopurinol in the treatment of adult patients with ...

    Report | 27-10-2014

  5. Simeprevir (Olysio) for the indication chronic hepatitis C

    The therapeutic value of simeprevir in combination with pegIFN and ribavirin for the treatment of chronic hepatitis C genotype 1 ...

    Report | 22-09-2014

  6. Mannitol (Bronchitol) for the indication 'adult patients with cystic fibrosis

    The WAR has approved a pharmacotherapeutic report for the medicine mannitol (Bronchitol) capsules with dry powder for inhalation. ...

    Report | 28-07-2014

  7. Dolutegravir (Tivicay) for the indication infection with HIV-1

    The WAR has approved a pharmacotherapeutic report for the medicine dolutegravir (Tivicay). In determining its therapeutic value, ...

    Report | 28-07-2014

  8. Dike-Reeve of the health care polder

    Publication | 30-06-2014

  9. Sofosbuvir (Sovaldi) for the indication chronic hepatitis C in adult patients

    Sofosbuvir for the treatment of chronic hepatitis C in adult patients has added therapeutical value in comparison to relevant ...

    Report | 14-04-2014

  10. Macitentan (Opsumit) for the indication pulmonary arterial hypertension WHO class II to III

    The WAR has approved a pharmacotherapeutic report for the medicine macitentan (Opsumit®; an endothelin-1-receptor antagonist). In ...

    Report | 24-03-2014